Princeton University's annual research magazine, Discovery: Research at Princeton, has featured the Ploss Lab's ongoing COVID research. The article states:
To make SARS-CoV-2 safer for handling in the laboratory, Alexander Ploss, associate professor of molecular biology, and his team are developing a less virulent version of the virus. The strain, developed by reverse engineering the virus, lacks components needed to infect cells. Researchers can use this non-infectious version to test new therapies.
To search for treatments for SARS-CoV-2 acute respiratory distress syndrome, the team collaborated with scientists at Boston University to develop new mouse models that contain human lung tissue. The Ploss lab and their collaborators in Boston are working on a vaccine against the virus modeled on a successful vaccine against yellow fever.
“In addition to these lines of experiments, we have been able to establish very productive collaborations with others at Princeton to identify components that are essential for SARS-CoV-2 entry and replication,” Ploss said.
The full article can be found here or in the latest issue of Discovery: Research at Princeton.